<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01435798</url>
  </required_header>
  <id_info>
    <org_study_id>R01NS041503</org_study_id>
    <nct_id>NCT01435798</nct_id>
  </id_info>
  <brief_title>Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial</brief_title>
  <official_title>Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan Dose Response Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Neurological Disorders and Stroke (NINDS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled, double-blind 4x4 crossover clinical trial was part of a
      larger NIH-funded study to evaluate the analgesic efficacy of three doses of chronic oral
      (PO) dextromethorphan compared to placebo in central neuropathic pain following spinal cord
      injury. Subjects' maximally tolerated doses (MTD) were first determined to establish
      individual dose-analgesic response relationships in a run-in period; following a washout
      period, subjects were then randomized to receive an order of four doses of dextromethorphan
      (including placebo) in a 4x4 Latin square cross-over design.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2003</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Pain Intensity (Percent Change From Baseline)</measure>
    <time_frame>1st week of maintenance period (week prior to hospital admission for nested study; subjects traveled to Boston on days 6-7 of the maintenance period)</time_frame>
    <description>Primary outcome was percent change from baseline in mean pain intensity (transformed Gracely Scale; 0-35). Baseline was defined as the week prior to randomization. The greater the percent change, the bigger the reduction in pain intensity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Satisfaction</measure>
    <time_frame>Last week prior to admission (end of 1-week maintenance period)</time_frame>
    <description>Satisfaction with study treatment assessed over the 7 days prior to admission (5-point categorical scale)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Central Neuropathic Pain</condition>
  <condition>Allodynia</condition>
  <condition>Spinal Cord Injury</condition>
  <arm_group>
    <arm_group_label>0% MTD Dex</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0% MTD Dextromethorphan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>25% MTD Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>25% MTD Dextromethorphan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>50% MTD Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50% MTD Dextromethorphan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>100% MTD Dex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100% MTD Dextromethorphan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextromethorphan</intervention_name>
    <description>0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period</description>
    <arm_group_label>0% MTD Dex</arm_group_label>
    <arm_group_label>25% MTD Dex</arm_group_label>
    <arm_group_label>50% MTD Dex</arm_group_label>
    <arm_group_label>100% MTD Dex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male or female adults, age 18 to 70 with central neuropathic pain for a
             minimum of 3 months following SCI as confirmed by neurologic evaluation, with an
             average pain intensity score of at least moderate over at least 50% of the day for the
             7 days prior to the screening visit and over the 7 days prior to starting study
             medication.

          2. Subjects used no medication or a stabilized medication regimen for chronic and
             well-controlled medical conditions

          3. Serum laboratory examination obtained at study entry:

               -  Liver function tests (albumin within 20% of normal, SGOT/SGPT within 50% of
                  normal).

               -  For women of childbearing age: negative serum beta HCG.

          4. Postmenopausal women, or be physically incapable of childbearing, or be practicing an
             acceptable method of birth control.

          5. Normal cognitive function.

          6. Normal communicative ability (English).

          7. Ability to demonstrate competence in recording five times daily in pain diary for 1
             week (with 100% compliance), and in completing required questionnaires.

          8. Signed informed consent.

        Exclusion Criteria:

          1. Pregnancy or breast-feeding.

          2. Renal or hepatic dysfunction.

          3. Significant cardiac disease (e.g. MI within 1 year).

          4. Signs or symptoms of central neurological disorder, excluding SCI.

          5. Severe psychological disorder requiring treatment.

          6. Concurrent use of monoamine oxidase inhibitors within 2 weeks prior to study entry.

          7. Use of known CYP2D6 (but not CYP3A4) inhibitors or inducers.

          8. History of hypersensitivity or intolerance to dextromethorphan or lidocaine.

          9. Chronic substance abuse, including alcohol.

         10. Participation in a study of an investigational drug or device within 30 days prior to
             screening for this study.

         11. Poor metabolizer of P450 2D6 substrates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Translational Pain Research, Brigham and Women's Hospital (Disclosure: Patent)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Translational Pain Research, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.paintrials.org</url>
    <description>Translational Pain Research, Brigham and Women's Hospital</description>
  </link>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 15, 2011</study_first_submitted>
  <study_first_submitted_qc>September 16, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2011</study_first_posted>
  <results_first_submitted>June 26, 2014</results_first_submitted>
  <results_first_submitted_qc>February 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 4, 2017</results_first_posted>
  <last_update_submitted>February 15, 2017</last_update_submitted>
  <last_update_submitted_qc>February 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Christine N. Sang, MD, MPH</investigator_full_name>
    <investigator_title>Director, Translational Pain Research</investigator_title>
  </responsible_party>
  <keyword>chronic pain</keyword>
  <keyword>central neuropathic pain</keyword>
  <keyword>spinal cord injury</keyword>
  <keyword>dextromethorphan</keyword>
  <keyword>lidocaine</keyword>
  <keyword>combination therapy</keyword>
  <keyword>analgesia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
    <mesh_term>Hyperalgesia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dextromethorphan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited nationally from referring physicians, through advertisements, and through existing databases.</recruitment_details>
      <pre_assignment_details>During the screening visit, P450 2D6 phenotype status was determined for each subject to identify drug-metabolizing capacity; those who were P450 2D6 poor-metabolizers were excluded. Following screen, each subject entered a dose escalation period to determine his/her maximum tolerated dose (MTD), prior to randomization.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dextromethorphan Dose Response (DDR) Clinical Trial</title>
          <description>Each subject received four doses of dextromethorphan; 0% (placebo), 25%, 50%, and 100% of the maximum tolerated dose in a balanced randomized order. Each dose was administered for a period of 28 days; on day 21 of each phase, subjects traveled to the study site to undergo study procedures in a nested clinical trial (not described here).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26">Crossover design</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>0% MTD</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>25% MTD</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>50% MTD</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>100% MTD</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25">Crossover design</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dextromethorphan Dose Response Clinical Trial</title>
          <description>Each subject received four doses of dextromethorphan; 0% (placebo), 25%, 50%, and 100% of the maximum tolerated dose in a balanced randomized order. Each dose was administered for a period of 28 days; on day 21 of each phase, subjects traveled to the study site to undergo study procedures in a nested clinical trial (not described here).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.84" spread="11.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Pain Intensity (Percent Change From Baseline)</title>
        <description>Primary outcome was percent change from baseline in mean pain intensity (transformed Gracely Scale; 0-35). Baseline was defined as the week prior to randomization. The greater the percent change, the bigger the reduction in pain intensity.</description>
        <time_frame>1st week of maintenance period (week prior to hospital admission for nested study; subjects traveled to Boston on days 6-7 of the maintenance period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% MTD Dex</title>
            <description>0% (placebo) of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O2">
            <title>25% MTD Dex</title>
            <description>25% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O3">
            <title>50% MTD Dex</title>
            <description>50% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O4">
            <title>100% MTD Dex</title>
            <description>100% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Pain Intensity (Percent Change From Baseline)</title>
          <description>Primary outcome was percent change from baseline in mean pain intensity (transformed Gracely Scale; 0-35). Baseline was defined as the week prior to randomization. The greater the percent change, the bigger the reduction in pain intensity.</description>
          <units>Percent change from baseline</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.006" spread="0.01"/>
                    <measurement group_id="O2" value="-0.018" spread="0.005"/>
                    <measurement group_id="O3" value="-0.073" spread="0.01"/>
                    <measurement group_id="O4" value="-0.24" spread="0.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Satisfaction</title>
        <description>Satisfaction with study treatment assessed over the 7 days prior to admission (5-point categorical scale)</description>
        <time_frame>Last week prior to admission (end of 1-week maintenance period)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>0% MTD Dex</title>
            <description>0% (placebo) of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O2">
            <title>25% MTD Dex</title>
            <description>25% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O3">
            <title>50% MTD Dex</title>
            <description>50% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
          <group group_id="O4">
            <title>100% MTD Dex</title>
            <description>100% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
          </group>
        </group_list>
        <measure>
          <title>Satisfaction</title>
          <description>Satisfaction with study treatment assessed over the 7 days prior to admission (5-point categorical scale)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Not Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fairly Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Very/Extremely Satisfied</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected post-dose through the end of treatment in each arm.</time_frame>
      <desc>All anticipated and unanticipated post-dose adverse events that were possibly, probably, or definitely related to the study drug are reported.</desc>
      <group_list>
        <group group_id="E1">
          <title>0% MTD Dex</title>
          <description>0% (placebo) of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
        </group>
        <group group_id="E2">
          <title>25% MTD Dex</title>
          <description>25% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
        </group>
        <group group_id="E3">
          <title>50% MTD Dex</title>
          <description>50% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
        </group>
        <group group_id="E4">
          <title>100% MTD Dex</title>
          <description>100% of maximum tolerated dose of dextromethorphan; dose was administered for a period of 28 days, and on day 21, subjects traveled to the study site to undergo additional study procedures.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="16" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitis</sub_title>
                <description>Not present at baseline, defined as:1) prior to randomization, in DDR; 2) Prior to lido infusion, on 100% Dex, in D/L. In DDR, all AEs were of mild intensity. In D/L, AEs were assessed at Cmax and were &gt;= mild. No infusions were terminated for AEs.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Sedation</sub_title>
                <description>Not present at baseline, defined as:1) prior to randomization, in DDR; 2) Prior to lido infusion, on 100% Dex, in D/L. In DDR, all AEs were of mild intensity. In D/L, AEs were assessed at Cmax and were &gt;= mild. No infusions were terminated for AEs.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Blurry Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Interference with Alertness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Interference with Ability to Drive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christine N. Sang, MD, MPH</name_or_title>
      <organization>Translational Pain Research, Brigham and Women's Hospital</organization>
      <phone>617-525-7246</phone>
      <email>paintrials@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

